In 2010, toxigenic Vibrio cholerae was newly introduced to Haiti. Because resources are limited, decision-makers need to understand the effect of different preventive interventions. We built a static model to estimate the potential number of cholera cases averted through improvements in coverage in water, sanitation and hygiene (WASH) (i.e., latrines, point-of-use chlorination, and piped water), oral cholera vaccine (OCV), or a combination of both. We allowed indirect effects and non-linear relationships between effect and population coverage. Because there are limited incidence data for endemic cholera in Haiti, we estimated the incidence of cholera over 20 years in Haiti by using data from Malawi. Over the next two decades, scalable WASH interventions could avert 57,949-78,567 cholera cases, OCV could avert 38,569-77,636 cases, and interventions that combined WASH and OCV could avert 71,586-88,974 cases. Rate of implementation is the most influential variable, and combined approaches maximized the effect.
In 2010, toxigenic Vibrio cholerae was newly introduced to Haiti. Because resources are limited, decision-makers need to understand the effect of different preventive interventions. We built a static model to estimate the potential number of cholera cases averted through improvements in coverage in water, sanitation and hygiene (WASH) (i.e., latrines, point-of-use chlorination, and piped water), oral cholera vaccine (OCV), or a combination of both. We allowed indirect effects and non-linear relationships between effect and population coverage. Because there are limited incidence data for endemic cholera in Haiti, we estimated the incidence of cholera over 20 years in Haiti by using data from Malawi. Over the next two decades, scalable WASH interventions could avert 57,949-78,567 cholera cases, OCV could avert 38,569-77,636 cases, and interventions that combined WASH and OCV could avert 71,586-88,974 cases. Rate of implementation is the most influential variable, and combined approaches maximized the effect.
In October 2010, cholera was introduced to earthquake-stricken Haiti.1 Within days of its introduction, a National Cholera Surveillance System was implemented.1 Through June 30, 2013, Haiti had reported 663,134 cases of cholera (Figure 1)2; of these, 366,995 (55.3%) were hospitalized and 8160 (1.2%) died. As we approach the three-year mark, cholera will likely be considered endemic to Haiti.
Figure 1.
Total (n = 663,134) cholera cases by week, Haiti, October 20, 2010–June 30, 2013.
Total (n = 663,134) cholera cases by week, Haiti, October 20, 2010–June 30, 2013.Water, sanitation, and hygiene (WASH) interventions, such as latrines, point-of-use chlorination and piped water, have long been recognized as effective prevention measures against cholera and other diarrheal diseases.3–12 In 2008, 63% of the Haitian population had access to improved water and 17% to improved sanitation.13 In 2010, after the earthquake, the Haitian Directorate for Potable Water and Sanitation reported that 26% of the rural population received improved water and 10% improved sanitation; in the Port-au-Prince metropolitan area, the coverage was 35% and 20%, respectively (Haitian Directorate for Potable Water and Sanitation five-year plan). Many public health scientists believe that sustained improvements in access to safe water and sanitation can eliminate transmission of cholera in Haiti, citing interventions used throughout South and Central America in the 1990s.14,15 The WASH interventions, including hand washing, have the additional benefit of reducing the incidence of other diarrheal and respiratory diseases.3,5,16,17 Although improving water and sanitation infrastructure is the ultimate goal of the Haitian Government and the international community, it will take considerable time.18Oral cholera vaccine (OCV) has been proposed as an effective adjunct for cholera control in endemic and epidemic settings.19,20 Two whole-cell, killed, World Health Organization–prequalified OCVs are available: Dukoral® (Crucell, Stockholm, Sweden) and Shanchol™ (Shantha Biotechnics, Hyderabad, India). Both vaccines require two doses given two weeks apart, with protective immunity developing approximately one week after the second dose.21,22 The Haitian government sanctioned two pilot studies23 to assess the acceptability and feasibility of Shanchol™ vaccine, one in urban Haiti and one in rural Haiti.24 Based on these pilot study findings and findings from previous OCV studies, the Pan American Health Organization has recommended targeted or mass OCV campaigns that use Shanchol™ as an intermediate bridge to reduce cholera transmission in Haiti while improvements in water and sanitation infrastructure are implemented.24 We present results of a model that illustrates the potential impact of WASH and OCV interventions independently and in combination. These results can aid public health decision makers in allocating resources to prevent cholera transmission in Haiti.
Methods
We used Excel 2010 (Microsoft, Redmond, WA) to develop a spreadsheet-based, static mathematical model in which we allowed a degree of indirect protection (or herd immunity) for OCV and WASH interventions by including non-linear relationships between percentage of population covered and percentage of population effectively protected (i.e., for a given percentage vaccinated or who received WASH interventions, an additional percentage was also indirectly protected). For WASH interventions, we included latrines, point-of-use chlorination, and community piped water (standpipes). We divided Haiti's population into urban and rural elements. For both urban and rural populations, and for each intervention, we constructed three scenarios that illustrated potential rates-of-growth of coverage over 20 years. We also constructed scenarios in which we allowed a combination of WASH and OCV in rural and urban areas. In these combined scenarios, we conservatively assumed that persons who received OCV would not be covered by WASH interventions and vice versa. Thus, coverage for either WASH or for OCV interventions would never exceed 50%. We modeled 16 scenarios: six WASH, six OCV, and four that combined WASH and OCV interventions. For further details, see Online Supplemental Materials.
Demographics and expected annual incidence.
We used current population figures for Haiti stratified by rural and urban environments, and estimated population growth rate to project demographic growth over a 20-year period (Supplemental Table 1). Because toxigenic Vibrio cholerae was only recently introduced in Haiti, and cholera incidence has changed from an epidemic to an endemic pattern (Figure 1),2 there are no data describing the incidence of endemic cholera in Haiti over a 20-year period. Therefore, we estimated the 20-year annual incidence of endemic cholera in Haiti by using 1990–2010 annual incidence data from Malawi as reported to the World Health Organization.25 We chose Malawi because it faces similar socioeconomic challenges to those seen in Haiti (e.g., poor roads, relatively high infant mortality rate, large population without piped water, rates of literacy < 80%).26 We also performed sensitivity analyses by using annual incidence data for endemic cholera from Mozambique and India, as well as a set of hypothetical annual incidence data (Online Supplemental Material).
Intervention effectiveness.
For each intervention, we included non-linear relationships between coverage and effectiveness that take into account indirect protective effects27 (Figure 2). For OCV (Shanchol™), we fitted an exponential curve to the OCV (Dukarol®) coverage-effectiveness modeling data from Longini and others.28 (Figure 2; Supplemental Table 2). The randomized control trial data for Shanchol™ administered as a two-dose regimen showed a direct efficacy of 67% after two years, which is nearly identical to that for Dukarol®21 and 66% after three years.29,30 Therefore, we assumed that our use of the Dukarol® coverage-effectiveness curve as a proxy for the Shanchol™ coverage-effectiveness curve was reasonable. We did not examine partial vaccination effect (i.e., receiving only one dose). The OCV coverage in our model implies effective coverage with two doses of Shanchol™ vaccine, and in addition, assumes that all two dose recipients will receive one booster dose every three years thereafter (Supplemental Table 4). For latrines and point-of-use chlorination, we estimated non-linear curves based on data from two reviews of interventions3,5 (Figure 2; Supplemental Table 2). For piped water, we assumed a non-linear curve with a protective effect of 90% at 100% coverage (Figure 2; Supplemental Table 2). Because there are little data on the synergistic effect of one or more WASH interventions, we used a conservative approach and assumed no additive effect across the various combinations of possible WASH interventions.7 Therefore, we used a stepwise introduction of WASH interventions over time, and the intervention with the stronger protective effect supplanted the other (i.e., piped water > chlorinated water > latrines). For further detail, see the Online Supplemental Material.
Figure 2.
Coverage-effectiveness curves for various interventions. Black line indicates oral cholera vaccine; dark gray dotted line indicates piped water; gray dotted-dashed line indicates point-of-use chlorination; light gray dashed line indicates latrines.
Coverage-effectiveness curves for various interventions. Black line indicates oral cholera vaccine; dark gray dotted line indicates piped water; gray dotted-dashed line indicates point-of-use chlorination; light gray dashed line indicates latrines.
Intervention coverage over time.
For each urban (U) and rural (R) population, we modeled three rates of intervention implementation over 20 years for WASH (WASH/U 1, U 2, U 3 and WASH/R 1, R 2, R 3) and OCV (OCV/U 1, U 2, U 3 and OCV/R 1, R 2, R 3) interventions (Tables 1 and 2; Supplemental Figures 1, 3, and 4). We assumed that five persons shared one latrine and 50 persons shared one community piped water standpipe. Point-of use chlorination was assumed to occur at a household level. We also assumed that in the first five years of implementation, WASH resources would primarily be allocated towards point-of-use chlorination and that piped water would begin in year 6.
Table 1
Water, sanitation, and hygiene (WASH) scenarios with percentage of urban (U) and rural (R) Haitian population covered at years 0, 5, and 20*
Scenario
Intervention
Year 0 (%)
Year 5 (%)
Year 20 (%)
WASH/U1
Latrines
10
10
0
Point-of-use chlorination + L
20
80
25
Piped water + C + L
10
10
75
Total
40
100
100
WASH/U2
Latrines
10
10
0
Point-of-use chlorination + L
20
60
50
Piped water + C + L
10
10
50
Total
40
80
100
WASH/U3
Latrines
10
10
0
Point-of-use chlorination + L
20
40
80
Piped water + C + L
10
10
20
Total
40
60
100
WASH/R1
Latrines
10
30
0
Point-of-use chlorination + L
26
40
30
Piped water + C + L
0
0
70
Total
36
70
100
WASH/R2
Latrines
10
20
8
Point-of-use chlorination + L
26
30
42
Piped water + C + L
0
0
50
Total
36
50
100
WASH/R3
Latrines
10
10
10
Point-of-use chlorination + L
26
30
42
Piped water + C + L
0
0
25
Total
36
40
77
C = point-of-use chlorination; L = latrines.
Table 2
Oral cholera vaccine (OCV) scenarios with percentage of Haitian urban (U) and rural (R) population covered at years 0, 5, and 20
Scenarios
Year 0 (%)
Year 5 (%)
Year 20 (%)
OCV/U1
1
50
90
OCV/U2
1
20
60
OCV/U3
1
10
25
OCV/R1
1
50
65
OCV/R2
1
20
40
OCV/R3
1
10
25
In addition, we generated two scenarios that combined WASH and OCV for each of the urban and rural settings (Table 3) . The four combined scenarios differ in coverage rate achieved by year 20 for each WASH and OCV intervention. For example, in the first urban and rural combined scenarios (Combined/U1, Combined/R1), we assumed that OCV reached peak coverage of 20% at year 5 and then decreased to 5% by year 20. For the second urban and rural combined scenarios (Combined/U2, Combined/R2), we assumed that OCV coverage peaked at 10% in year 5 and then decreased to 0% by year 20.
Table 3
Combined oral cholera vaccine (OCV) and water, sanitation and hygiene (WASH) scenarios by percentage of Haitian urban (U) and rural (R) population covered, and at years 0, 5, and 20*
Scenarios
Interventions
Year 0 (%)
Year 5 (%)
Year 20 (%)
Combined/U1
OCV
1
20
5
WASH sub-total
40
50
50
Latrines
10
10
0
Point-of-use chlorination + L
20
30
0
Piped water + C + L
10
10
50
Combined/U2
OCV
1
10
0
WASH sub-total
40
50
50
Latrines
10
10
0
Point-of-use chlorination + L
20
30
25
Piped water + C + L
10
10
25
Combined/R1
OCV
1
20
5
WASH sub-total
36
40
50
Latrines
10
10
0
Point-of-use chlorination + L
26
30
0
Piped water + C + L
0
0
50
Combined/R2
OCV
1
10
0
WASH sub-total
36
40
50
Latrines
10
10
0
Point-of-use chlorination + L
26
30
25
Piped water + C + L
0
0
25
C = point-of-use-chlorination; L = latrines.
Number of cholera cases averted.
Using endemic cholera incidence data from Malawi, we calculated potential cases averted for each scenario by multiplying the estimated incidence and the protective effect of the intervention(s). Cumulative cases averted were discounted by 3% per year.31
Uncertainty/sensitivity analyses.
To assess the robust nature of our model, we performed uncertainty/sensitivity analyses in three steps. First, we varied the baseline incidence rates to see if the change in input would change our results. We used endemic cholera incidence data from Mozambique (1990–2010) and India (1961–1981) to model countries with a higher and a lower mean incidence, respectively. We also created hypothetical scenarios with stable, growing, and decreasing cholera incidence to determine whether different secular trends in annual incidence would change our results. Second, we varied the coverage-effectiveness curves for latrines, point-of-use chlorination, and community piped water to enable uncertainty of the estimates of the protective effectiveness of these WASH interventions. The ranges for their protective effectiveness at 100% intervention coverage are latrines (95% confidence interval = 8–46%), point-of-use chlorination (95% CI = 32–83%), and piped water 90% (default value), and 100% (complete protection) (Supplemental Figure 2). Third, we varied the implementation rate of WASH, OCV, or a combination of both interventions to determine how the number of cumulative cholera cases averted would vary.
OCV uncertainty/sensitivity analyses.
We varied OCV coverage at year 20 from 1% to 100%. We assumed that effective OCV coverage increased linearly for 20 years.
WASH uncertainty/sensitivity analyses.
For latrines, we assumed that in urban Haiti, the percentage of persons with access to latrines only remained the same for the first five years and then was gradually replaced by point-of-use chlorination or piped water; in rural Haiti, the latrine coverage increased at a constant rate from 10% at year 0 to 30% at year 5 and continues to increase at the same rate thereafter until it is gradually replaced by point-of-use chlorination or piped water. Point-of-use chlorination coverage remained at baseline (20% in urban areas and 26% in rural areas) through year 20, or increased to various levels by year 5 (30%, 50%, 70%, or 90% in urban and rural areas, respectively), increasing thereafter through year 20 in the absence of piped water. Piped water coverage remained at baseline (10% in urban areas and 0% in rural areas) for the first five years, increasing thereafter through year 20.
Combined WASH and OCV uncertainty/sensitivity analyses.
In our combined scenarios, we assumed that the respective coverage of OCV and WASH does not exceed 50%. Those persons who would receive OCV would not receive any WASH interventions and vice versa. We assumed that latrine only coverage remained at the baseline (10%) until those persons also received point-of-use chlorination or piped water interventions. Point-of-use chlorination coverage increased from baseline (20% for urban areas and 26% for rural areas) to 30% at year 5, and continued to increase at a constant rate until piped water replaced it (sensitivity analysis scenario 1); or its coverage remained unchanged at the baseline from year 0 to year 5 and remained unchanged for subsequent years until piped water replaced it (sensitivity analysis scenario 2). Piped water coverage remained at baseline (10% in urban areas and 0% in rural areas) for the first 5 years, and increased at a constant rate thereafter to reach 10%, 20%, 30%, 40%, or 50%, respectively, by year 20. The OCV coverage increased at a constant rate from 1% (baseline) at year 0, peaked at year 5, and decreased thereafter at a constant rate to reach 5% at year 20. We varied the OCV coverage attained at year 5 from 1% (baseline) to 50%. Finally, we ran two sets of sensitivity analyses of the four combined interventions in which we first assumed that OCV coverage increased at a constant rate from 1% baseline at year 0 and reached 50% at year 5, and then either decreased at a constant rate to 5% at year 20 or remained at 50% through year 20 (i.e., no decrease) (see Online Supplemental Material).
Results
We developed eight urban scenarios (three WASH, three OCV, and two WASH/OCV combined) and eight rural scenarios (three WASH, three OCV, and two WASH/OCV combined). WASH scenario 1 (WASH/R1 + WASH/U1) averted 78,567 cases of cholera. WASH scenario 2 (WASH/R2 + WASH/U2) averted 71,106 cases of cholera. WASH scenario 3 (WASH/R3 + WASH/U3) averted 57,949 cases of cholera (Tables 1 and 4, Figure 3).
Table 4
Comparisons of the cumulative number of cases of cholera averted by oral cholera vaccine (OCV) and water, sanitation and hygiene (WASH) scenarios applied to Haitian urban (U) and rural (R) populations by using Malawi, Mozambique, and India 20-year endemic cholera incidence data as baseline*
Baseline incidence rate as applied to Haiti†
U/R
WASH 1
WASH 2
WASH 3
OCV 1
OCV 2
OCV 3
Combi 1
Combi 2
Malawi (1990–2010)
U
42,828
41,072
34,794
38,793
29,704
19,093
46,213
38,913
R
35,739
30,034
23,155
38,843
27,964
19,476
42,761
32,673
Total
78,567
71,106
57,949
77,636
57,668
38,569
88,974
71,586
Mozambique (1990–2010)
U
61,879
59,313
49,427
59,223
45,931
29,529
65,384
54,827
R
52,541
43,865
33,452
59,229
43,085
30,121
62,704
47,076
Total
114,420
103,178
82,879
118,452
89,016
59,650
128,088
101,903
India (1961–1981)
U
3,711
3,530
3,010
3,421
2,508
1,588
4,124
3,473
R
2,911
2,454
1,956
3,437
2,387
1,620
3,753
2,856
Total
6,622
5,984
4,966
6,858
4,895
3,208
7,877
6,329
Combi = combination of WASH and OCV.
Total cumulative cholera incidence (with a discounting rate of 3% per year): Malawi baseline incidence rate scenario: 106,994 cases; Mozambique baseline incidence rate scenario: 142,754 cases; India baseline incidence rate scenario: 9,635 cases.
Figure 3.
Cumulative cases of cholera averted by water, sanitation and hygiene (WASH) interventions, oral cholera vaccine interventions (OCV) or a combination of both (Combi) over a 20-year period in Haiti, and assuming a baseline national cholera incidence rate from Malawi (1990–2010) applied to urban and rural Haiti.
Cumulative cases of cholera averted by water, sanitation and hygiene (WASH) interventions, oral cholera vaccine interventions (OCV) or a combination of both (Combi) over a 20-year period in Haiti, and assuming a baseline national cholera incidence rate from Malawi (1990–2010) applied to urban and rural Haiti.OCV scenario 1 (OCV/R1 + OCV/U1) averted 77,636 cases of cholera. OCV scenario 2 (OCV/R2 + OCV/U2) averted 57,668 cases of cholera. OCV scenario 3 (OCV/R3 + OCV/U3) averted 38,569 cases of cholera (Tables 2 and 4, Figure 3).The rate of intervention coverage extension had the largest effect on cases of cholera averted (the difference between scenarios 1, 2 and 3 for either WASH or OCV).Combined scenario 1 (Combined/R1 + Combined/U1) averted 88,974 cholera cases. Combined scenario 2 (Combined/R2 + Combined/U2) averted 71,586 cholera cases (Tables 3 and 4, Figure 3).In our sensitivity analyses, we found that although the absolute number of cases of cholera averted is sensitive to the expected number of cholera cases given different baseline annual incidence of cholera, the relative effect of each intervention scenario is the same (Figure 4
; Supplemental Figure 1). Our sensitivity analysis of combined interventions (Figure 5
) demonstrated decreasing returns on investment (marginal increase of the number of cholera cases averted) when OCV coverage at year 5 and piped water coverage at year 20 are high. The OCV coverage of 30% at year 5 achieved similar outcomes with that of 50% coverage at year 5, regardless of piped water coverage of 10–50% at year 20 (Online Supplemental Material).
Figure 4.
Cumulative cases of urban (U) cholera cases averted by water, sanitation and hygiene (WASH/U1), oral cholera vaccine (OCV/U1) and a combination of WASH and OCV (Combined/U 1) scenarios when 20-year baseline annual incidence data from Malawi (1990–2010), Mozambique (1990–2010) and India (1961–1981) are applied to Haiti demographic data.
Figure 5.
Cumulative cholera cases averted over 20 years in Haiti by combined water, sanitation and hygiene (WASH) and oral cholera vaccine (OCV) intervention scenarios. The x-axis refers to OCV coverage at year 5, and the different lines refer to the proportion of total piped water coverage (10%, 20%, 30%, 40%, and 50%) at year 20. We assumed that 1) persons who received OCV would not be covered by WASH interventions and vice versa; 2) WASH and OCV interventions never exceed 50%, respectively; 3) point-of-use chlorination increases from 20% (urban), or 26% (rural) and will remain the same until piped water takes over (provided assumption 1 met); 4) latrine coverage remains 10% until it is taken over by point-of-use chlorination or piped water; 5) piped water baseline = 0% in rural areas and 10% in urban areas, and piped water coverage starts increasing at a constant rate from year 6 onwards; and 6) OCV coverage increases at a constant rate from 1% baseline at year 0, peaks at year 5 and decreases thereafter at a constant rate to reach 5% at year 20.
Cumulative cases of urban (U) cholera cases averted by water, sanitation and hygiene (WASH/U1), oral cholera vaccine (OCV/U1) and a combination of WASH and OCV (Combined/U 1) scenarios when 20-year baseline annual incidence data from Malawi (1990–2010), Mozambique (1990–2010) and India (1961–1981) are applied to Haiti demographic data.Cumulative cholera cases averted over 20 years in Haiti by combined water, sanitation and hygiene (WASH) and oral cholera vaccine (OCV) intervention scenarios. The x-axis refers to OCV coverage at year 5, and the different lines refer to the proportion of total piped water coverage (10%, 20%, 30%, 40%, and 50%) at year 20. We assumed that 1) persons who received OCV would not be covered by WASH interventions and vice versa; 2) WASH and OCV interventions never exceed 50%, respectively; 3) point-of-use chlorination increases from 20% (urban), or 26% (rural) and will remain the same until piped water takes over (provided assumption 1 met); 4) latrine coverage remains 10% until it is taken over by point-of-use chlorination or piped water; 5) piped water baseline = 0% in rural areas and 10% in urban areas, and piped water coverage starts increasing at a constant rate from year 6 onwards; and 6) OCV coverage increases at a constant rate from 1% baseline at year 0, peaks at year 5 and decreases thereafter at a constant rate to reach 5% at year 20.In our final sensitivity analysis, we explored scenarios to assess the impact on cases averted after a more rapid scale up of OCV coverage by year 5, as well as scenarios with sustained OCV coverage to year 20 (Table 5) . In our four combined scenarios described in Table 3, OCV coverage reached either 20% or 10% at year 5, and decreased to 5% or 0% by year 20, respectively (Combined/U1, Combined/R1, Combined/U2, Combined/R2). For Combined/U1 + R1, effective OCV coverage increased from 1% at year 0 at a constant rate, reached 20% at year 5, then decreased at a constant rate to 5% at year 20 (Table 3), thereby averting 88,974 cases over 20 years (Table 4). If in this scenario, effective OCV coverage was allowed to reach 50% at year 5, and then decrease at a constant rate to 5% at year 20, an additional 6,738 cases (95,712 cases) would be averted (Table 5). For Combined/U2 + R2, effective OCV coverage increased from 1% at year 0 at a constant rate, reached 10% at year 5, then decreased at a constant rate at 0% at year 20 (Table 3), thereby averting 71,586 cases over 20 years (Table 4). If in this scenario, effective OCV coverage were allowed to reach 50% at year 5, and then decrease at a constant rate to 5% at year 20, an additional 23,933 (95,519 cases) would be averted (Table 5). However, we estimated very small further increases in cases averted when we allowed for effective OCV coverage to reach 50% by year 5 and remain at that level to year 20 (Table 5). For example, in modified scenario Combined/U1 + R1, sustaining 50% coverage from year 5 through year 20 resulted in 95,777 cases averted (i.e., an additional 65 cases averted). Similar modest increases in case averted (95,703 cases averted; i.e., an additional 184 cases averted) were estimated for Combined/U2 + R2 (Table 5). For results of the other sensitivity/uncertainty analyses, see Online Supplemental Material.
Table 5
Cumulative number of cases averted in sensitivity analyses of additional combined scenarios of WASH and OCV in urban (U) and rural (R) Haiti*
Analysis
Combined/U1
Combined/U2
Combined/R1
Combined/R2
Combined/U1 + R1
Combined/U2 + R2
Main analysis in Table 3
46,213
38,913
42,761
32,673
88,974
71,586
50% OCV at year 5 decreasing to 5% at year 20†
48,337 (+2,124)
48,189 (+9,276)
47,375 (+4,614)
47,330 (+14,657)
95,712 (+6,738)
95,519 (+23,933)
Sustained 50% OCV from year 5 to 20†
48,371 (+34)
48,298 (+109)
47,406 (+31)
47,405 (+75)
95,777 (+65)
95,703 (+184)
Incremental differences are indicated in parentheses.
All other assumptions are the same as the combination scenarios as described in Table 3. WASH = water, sanitation, and hygiene; OCV = oral cholera vaccine.
Discussion
Our results demonstrate that the rate of expanding coverage of WASH and OCV interventions affects the cumulative number of cases of cholera averted. The scenarios demonstrate that the modeled WASH and OCV interventions averted similar numbers of cholera cases. The assumptions of coverage for this model took into consideration the theoretical implementation of WASH and OCV interventions. Our goal was to demonstrate the scope of results given different rates of implementation and levels of coverage attained through a variety of scenarios, as well as with the sensitivity and uncertainty analyses. Scenarios that combined WASH and OCV interventions were most effective, which supports current efforts to implement both interventions when feasible.24The WASH infrastructure provides a long-term, sustainable solution for prevention of cholera.12 Evidence from Europe and North America over the past two centuries, and more recently from Latin America, demonstrate that as water and sanitation coverage improves, the risk of epidemic or endemic cholera transmission is greatly reduced.12,14,15 WASH also prevents the transmission of many other diarrheal diseases, which in Haiti, as in many developing countries, is a leading killer of children less than five years of age.32,33 The overall benefit of expanding WASH coverage extends far beyond its effect on cholera alone.The OCVs should help reduce the burden of cholera while WASH coverage is expanded, given the considerable amount of time required to improve WASH infrastructure (e.g., piped water and sewers). However, an OCV program should not be considered as a long-term alternative substitute for WASH. Implementation of OCVs will present its own challenges. Currently available OCVs are not 100% efficacious, induced immunity wanes over time thereby requiring periodic booster dosing, and today's globally available OCV supply is not sufficient to vaccinate the entire Haitian population with the required two-dose regimen. In addition, evidence from the routine childhood expanded program for immunizations and recent nationwide vaccine campaigns in Haiti has demonstrated varying ranges of coverage.34–37 Although rapid expansion of effective OCV coverage to 50% of Haitian population (10 million doses of administered vaccine or more) by year 5 may avert an additional 6,000–24,000 cases (Table 5), such rapid expansion is likely beyond the country's current capacity. Therefore, we highlight coverage scenarios (Table 3) in our model that we believe could be realistically achieved based on Haiti's recent experience with routine expanded program for immunizations and vaccine campaigns.Our study has several limitations. First, we chose a static model while simultaneously incorporating an indirect effect by applying non-linear coverage-effective curves to WASH and OCV interventions. Thus, the model takes into account the current effect of an intervention (direct and indirect protection) and is an improvement over a classical static model. Unlike a model that simulates the transmission dynamics of cholera over time (e.g., ordinary differential equation models),38 a static model does not account for the future effect of the current intervention because the baseline incidence does not take into account the intervention applied in the previous year(s). However, our static model, like others,39,40 avoids having to estimate uncertain and unknown parameters required for dynamic models that explore the impact of multiple interventions introduced at various stages over time.41 More data will be needed to reduce the parameter uncertainty of existing dynamic models of cholera for Haiti.41,42 Second, although we accounted for population growth, we did not account for the likely migration of the Haitian population from rural to urban areas over the next 20 years. Third, we recognize that the baseline 20-year annual cholera incidence data from Malawi, Mozambique, and India that we used as illustrations for medium, high, and low incidence, respectively, may have been subject to under-reporting. However, our findings were robust across all three baseline country scenarios. However, it is clear that every country's experience with endemic cholera is unique. Only time will tell what Haiti's experience will be. Fourth, apart from modeling urban and rural Haiti separately, we did not study the impact of geographic variation on cholera incidence and intervention implementation (e.g., targeted immunization). Fifth, we acknowledge the uncertainty associated with the coverage-effectiveness curve used for each intervention. However, because data are sparse for OCV and WASH intervention coverage-effectiveness curves, we used modeling outputs of Longini and others28 to fit our exponential curves for OCV, and we also applied exponential curves to the WASH coverage-effectiveness relationship.27Our study emphasizes that intervention coverage affects variation in estimated number of cumulative cholera cases averted over an extended period, and demonstrates the probable synergistic effects of WASH and OCV when used in combination. Our study should not be interpreted as an exact prediction for the number of cholera cases that could be averted in Haiti under the scenarios outlined, but it serves to demonstrate that WASH and OCV interventions can play an important role in decreasing the burden of cholera, and that maximizing intervention coverage is the central variable to their success. Transmission and intervention dynamics need to be understood so that informed decisions can be made about how to allocate limited resources. The Haitian Government recently released its National Plan for the Elimination of Cholera.18 This plan outlines a combination of public health interventions that include the use of OCV while expanding access to clean water and sanitation. Our study suggests that this combined strategy will be effective.Supplemental Datas.
Authors: Lorna Fewtrell; Rachel B Kaufmann; David Kay; Wayne Enanoria; Laurence Haller; John M Colford Journal: Lancet Infect Dis Date: 2005-01 Impact factor: 25.071
Authors: Ezra J Barzilay; Nicolas Schaad; Roc Magloire; Kam S Mung; Jacques Boncy; Georges A Dahourou; Eric D Mintz; Maria W Steenland; John F Vertefeuille; Jordan W Tappero Journal: N Engl J Med Date: 2013-01-09 Impact factor: 91.245
Authors: Christopher J L Murray; Theo Vos; Rafael Lozano; Mohsen Naghavi; Abraham D Flaxman; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Diego Gonzalez-Medina; Richard Gosselin; Rebecca Grainger; Bridget Grant; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Francine Laden; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Daphna Levinson; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Charles Mock; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Natasha Wiebe; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Mohammad A AlMazroa; Ziad A Memish Journal: Lancet Date: 2012-12-15 Impact factor: 79.321
Authors: Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish Journal: Lancet Date: 2012-12-15 Impact factor: 79.321
Authors: Julien Graveleau; Maria Eleanor Reserva; Alama Keita; Roberto Molinari; Guillaume Constantin De Magny Journal: Front Public Health Date: 2021-04-29
Authors: Dang Duc Anh; Anna Lena Lopez; Hung Thi Mai Tran; Nguyen Van Cuong; Vu Dinh Thiem; Mohammad Ali; Jacqueline L Deen; Lorenz von Seidlein; David A Sack Journal: PLoS Med Date: 2014-09-02 Impact factor: 11.069
Authors: Carissa F Etienne; Jordan W Tappero; Barbara J Marston; Thomas R Frieden; Thomas A Kenyon; Jon K Andrus Journal: Am J Trop Med Hyg Date: 2013-10 Impact factor: 2.345
Authors: Katharine Robb; Clair Null; Peter Teunis; Habib Yakubu; George Armah; Christine L Moe Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345